Még nem toboroz
Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations
NCT07738887· 2. fázis· The Lymphoma Academic Research Organisation· Forrás
Még nem toboroz
FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial
NCT07576452· 4. fázis· University Hospital, Clermont-Ferrand· Forrás
Még nem toboroz
Personnalized Immunotherapy in Patients With Stage III Non-small Cell Lung Cancer
NCT07759492· 2. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás
Még nem toboroz
Tenecteplase for the treatment of acute stroke in the late time window before inter-hospital transfer for thrombectomy: a randomized controlled trial
2026-525280-40-00· 3. fázis· Fondation A De Rothschild· Forrás
Még nem toboroz
Early Corticosteroids in Severe Influenza Pneumonia, a phase III randomized controlled trial
2025-524976-40-00· 3. fázis· Centre Hospital Region Metz Thionville· Forrás
Toboroz
A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
NCT07465757· 2. fázis· Puma Biotechnology, Inc.· Forrás
Még nem toboroz
Topical Clobetasol Propionate for Inflammatory Hand Osteoarthritis
NCT07812701· 2. fázis· Assistance Publique - Hôpitaux de Paris· Forrás
Még nem toboroz
Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock
NCT07569536· 3. fázis· Hospices Civils de Lyon· Forrás
Még nem toboroz
BETARGET : Randomized trial of individualizing BETA-lactam taRGET combining therapeutic drug monitoring, minimal inhibitory concentration and model-based dose adjustment, in Intensive Care Units patients with gram negative bacilli infection
2025-522819-42-01· 4. fázis· Centre Hospitalier Universitaire De Rennes· Forrás
Toboroz
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
NCT07621809· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
PALETTE - Trial for personalisation of sepsis treatment in children and adults
2025-521371-31-00· 2. fázis· Assistance Publique Hopitaux De Paris· Forrás
Toboroz
Optimal Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Open Label Interventional, Multicenter Study
NCT07616687· 4. fázis· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Forrás
Toboroz
Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN
NCT07264075· 3. fázis· Groupe Oncologie Radiotherapie Tete et Cou· Forrás
Toboroz
Trial assessing fianlimab plus cemiplimab plus chemotherapy or cemiplimab plus chemotherapy in patients with pleural mesothelioma
2024-519208-29-00· 2. fázis· Intergroupe Francophone De Cancerologie Thoracique· Forrás
Toboroz
A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice
NCT07556159· 4. fázis· Sanofi· Forrás
Toboroz
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
NCT07215702· 2. fázis· AstraZeneca· Forrás
Toboroz
FILOWM4-WaZaBi: "Open label phase 2 study evaluating the efficacy and tolerance of a zanubrutinib and BGB-11417 combination in patients previously treated for Waldenström macroglobulinemia"
2023-505781-28-00· 2. fázis· French Innovative Leukemia Organization· Forrás
Még nem toboroz
A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)
2025-521090-14-00· 2. fázis· Assistance Publique Hopitaux De Paris· Forrás
Még nem toboroz
Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer
NCT07150403· 2. fázis· Federation Francophone de Cancerologie Digestive· Forrás
Toboroz
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
NCT06908993· 3. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás
Toboroz
Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC.
2024-516906-47-00· 2/3. fázis· Daiichi Sankyo Inc.· Forrás
Toboroz
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
NCT07227402· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
NCT07205822· 3. fázis· AstraZeneca· Forrás
Toboroz
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853· 3. fázis· Pfizer· Forrás
Toboroz
Prophylactic Anti-aRrhythmic therapy with Amiodarone in critically ill patients admitted for an out-of-hospital Cardiac Arrest with initial shockable rhythm._PARACA
2023-510099-30-00· 3. fázis· Centre Hospitalier De Versailles· Forrás
Toboroz
Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy
NCT06680596· 2. fázis· UNICANCER· Forrás
Toboroz
Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
NCT06606730· 3. fázis· UNICANCER· Forrás
Toboroz
Evaluation of 200 mg of Rituximab Every 6 Months as Maintenance Treatment of Rituximab-treated Patients With Rheumatoid Arthritis
NCT06906549· 4. fázis· University Hospital, Strasbourg, France· Forrás
Toboroz
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
NCT06918002· 3. fázis· Intergroupe Francophone du Myelome· Forrás
Toboroz
IFM2024-06 : A multi-center, open-label, phase 2 randomized study of elranatamab plus lenalidomide versus daratumumab plus lenalidomide as post transplantation maintenance therapy in patients with newly-diagnosed myeloma
2024-517325-43-00· 2. fázis· Centre Hospitalier Universitaire De Nantes· Forrás
Még nem toboroz
Effect of Long-term Carvedilol to Prevent Decompensation or Death in Patients With Asymptomatic Child-Pugh A5 to B8 Cirrhosis and Clinically Significant Portal Hypertension: a Multicenter Double-blind Randomized Control Trial
NCT06263816· 3. fázis· University Hospital, Tours· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357· 3. fázis· Biogen· Forrás
Toboroz
MODULO
NCT06774872· 3. fázis· Centre De Recherches Et D'Etudes Sur La Pathologie Tropicale Et Le Sida· Forrás
Toboroz
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060· 3. fázis· AstraZeneca· Forrás
Toboroz
A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy
NCT06854640· 1. fázis· Bayer· Forrás
Toboroz
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
NCT05973864· 2. fázis· UNICANCER· Forrás
Toboroz
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723· 3. fázis· AstraZeneca· Forrás
Toboroz
PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatellite unstable or mismatch repair-deficient locally advanced rectal cancer patients: a randomized phase II trial
2024-510772-20-00· 2. fázis· Centre Hospitalier Universitaire De Dijon· Forrás
Még nem toboroz
Stop Treatment in gout
2024-515714-40-00· 2. fázis· Assistance Publique Hopitaux De Paris· Forrás
Toboroz
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
NCT06717347· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637· 3. fázis· Pfizer· Forrás
Toboroz
Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N
NCT06640725· 2. fázis· Groupe Oncologie Radiotherapie Tete et Cou· Forrás
Toboroz
Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage: the MONITORA Study
NCT06528431· 4. fázis· Centre Hospitalier Universitaire de Saint Etienne· Forrás
Toboroz
Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone
NCT06561854· 3. fázis· Assistance Publique - Hôpitaux de Paris· Forrás
Toboroz
Lessening Organ Dysfunction with VITamin C in septic ARDS
NCT04404387· 3. fázis· Assistance Publique Hopitaux De Paris· Forrás
Toboroz
Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.
NCT06180382· 4. fázis· Centre Hospitalier Universitaire de Saint Etienne· Forrás
Toboroz
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
NCT06456593· 2. fázis· Abivax S.A.· Forrás
Még nem toboroz
Safety and Efficacy of Apixaban Versus Warfarin in Peritoneal Dialysis Patients With Non Valvular Atrial Fibrillation: a Prospective, Randomised, Open-label, Blinded End-point Trial (APIDP2)
NCT06045858· 3. fázis· University Hospital, Caen· Forrás
Toboroz
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.
2023-509340-10-00· 3. fázis· OSE Immunotherapeutics· Forrás
Showing 50 of 100.